IBDEI2IB ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,40027,1,4,0)
 ;;=4^K75.81
 ;;^UTILITY(U,$J,358.3,40027,2)
 ;;=^5008828
 ;;^UTILITY(U,$J,358.3,40028,0)
 ;;=K75.89^^152^2003^16
 ;;^UTILITY(U,$J,358.3,40028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40028,1,3,0)
 ;;=3^Inflammatory Liver Disease,Oth Spec
 ;;^UTILITY(U,$J,358.3,40028,1,4,0)
 ;;=4^K75.89
 ;;^UTILITY(U,$J,358.3,40028,2)
 ;;=^5008829
 ;;^UTILITY(U,$J,358.3,40029,0)
 ;;=K76.4^^152^2003^21
 ;;^UTILITY(U,$J,358.3,40029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40029,1,3,0)
 ;;=3^Peliosis Hepatis
 ;;^UTILITY(U,$J,358.3,40029,1,4,0)
 ;;=4^K76.4
 ;;^UTILITY(U,$J,358.3,40029,2)
 ;;=^91041
 ;;^UTILITY(U,$J,358.3,40030,0)
 ;;=K71.50^^152^2003^25
 ;;^UTILITY(U,$J,358.3,40030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40030,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/o Ascites
 ;;^UTILITY(U,$J,358.3,40030,1,4,0)
 ;;=4^K71.50
 ;;^UTILITY(U,$J,358.3,40030,2)
 ;;=^5008799
 ;;^UTILITY(U,$J,358.3,40031,0)
 ;;=K71.51^^152^2003^26
 ;;^UTILITY(U,$J,358.3,40031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40031,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/ Ascites
 ;;^UTILITY(U,$J,358.3,40031,1,4,0)
 ;;=4^K71.51
 ;;^UTILITY(U,$J,358.3,40031,2)
 ;;=^5008800
 ;;^UTILITY(U,$J,358.3,40032,0)
 ;;=K71.7^^152^2003^29
 ;;^UTILITY(U,$J,358.3,40032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40032,1,3,0)
 ;;=3^Toxic Liver Disease w/ Fibrosis & Cirrhosis of Liver
 ;;^UTILITY(U,$J,358.3,40032,1,4,0)
 ;;=4^K71.7
 ;;^UTILITY(U,$J,358.3,40032,2)
 ;;=^5008802
 ;;^UTILITY(U,$J,358.3,40033,0)
 ;;=K71.8^^152^2003^33
 ;;^UTILITY(U,$J,358.3,40033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40033,1,3,0)
 ;;=3^Toxic Liver Disease w/ Oth Disorders of Liver
 ;;^UTILITY(U,$J,358.3,40033,1,4,0)
 ;;=4^K71.8
 ;;^UTILITY(U,$J,358.3,40033,2)
 ;;=^5008803
 ;;^UTILITY(U,$J,358.3,40034,0)
 ;;=K71.9^^152^2003^34
 ;;^UTILITY(U,$J,358.3,40034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40034,1,3,0)
 ;;=3^Toxic Liver Disease,Unspec
 ;;^UTILITY(U,$J,358.3,40034,1,4,0)
 ;;=4^K71.9
 ;;^UTILITY(U,$J,358.3,40034,2)
 ;;=^5008804
 ;;^UTILITY(U,$J,358.3,40035,0)
 ;;=K75.2^^152^2003^20
 ;;^UTILITY(U,$J,358.3,40035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40035,1,3,0)
 ;;=3^Nonspecific Reactive Hepatitis
 ;;^UTILITY(U,$J,358.3,40035,1,4,0)
 ;;=4^K75.2
 ;;^UTILITY(U,$J,358.3,40035,2)
 ;;=^5008826
 ;;^UTILITY(U,$J,358.3,40036,0)
 ;;=K75.3^^152^2003^13
 ;;^UTILITY(U,$J,358.3,40036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40036,1,3,0)
 ;;=3^Granulomatous Hepatitis NEC
 ;;^UTILITY(U,$J,358.3,40036,1,4,0)
 ;;=4^K75.3
 ;;^UTILITY(U,$J,358.3,40036,2)
 ;;=^5008827
 ;;^UTILITY(U,$J,358.3,40037,0)
 ;;=K76.6^^152^2003^22
 ;;^UTILITY(U,$J,358.3,40037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40037,1,3,0)
 ;;=3^Portal Hypertension
 ;;^UTILITY(U,$J,358.3,40037,1,4,0)
 ;;=4^K76.6
 ;;^UTILITY(U,$J,358.3,40037,2)
 ;;=^5008834
 ;;^UTILITY(U,$J,358.3,40038,0)
 ;;=F20.3^^152^2004^31
 ;;^UTILITY(U,$J,358.3,40038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40038,1,3,0)
 ;;=3^Undifferentiated/Atypical Schizophrenia
 ;;^UTILITY(U,$J,358.3,40038,1,4,0)
 ;;=4^F20.3
 ;;^UTILITY(U,$J,358.3,40038,2)
 ;;=^5003472
 ;;^UTILITY(U,$J,358.3,40039,0)
 ;;=F20.9^^152^2004^27
 ;;^UTILITY(U,$J,358.3,40039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,40039,1,3,0)
 ;;=3^Schizophrenia,Unspec
 ;;^UTILITY(U,$J,358.3,40039,1,4,0)
 ;;=4^F20.9
